Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-PanTumor03: datopotamab deruxtecan alone and in combinations in advanced or metastatic solid tumors
2023-509436-26-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Dec 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of datopotamab deruxtecan in endometrial cancer (EC), gastric cancer (GC), prostate cancer (PCa) and 4 more (7 arms), sponsored by AstraZeneca. Primary endpoints: Objective response rate, Safety and tolerability and 2 more. Planned start Dec 2022; status: authorised.
02
Drugs
datopotamab deruxtecan
03
Conditions
endometrial cancer (EC)gastric cancer (GC)prostate cancer (PCa)ovarian cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-509436-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509436-26-00.